Please contact our sales representative to learn more information about this reagents.
Background
Pamrevlumab (INN, development code FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. This drug was developed by FibroGen, Inc.